MedTrace Logo

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-05-08

No results posted yet for this study

Summary

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emnergize

Conditions

Interventions

BIOLOGICAL

Empasiprubart IV

Intravenous infusion of empasiprubart

OTHER

Placebo IV

Intravenous infusion of placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-16
Primary Completion
2027-10-07
Completion
2031-01-23
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Bulgaria
  • China
  • Czechia
  • Estonia
  • Georgia
  • Italy
  • Japan
  • Poland
  • Romania
  • Slovakia
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07091630 on ClinicalTrials.gov